CBAY Stock Price, Cymabay Therapeutics Inc Quote, Chart

Market Summary

USD32.48

Delayed

CBAY Stock Price

View Fullscreen

CBAY RSI Chart

CBAY Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-35.36

Price/Sales (Trailing)

119.92

Price/Free Cashflow

-51.06

CBAY Price/Sales (Trailing)

CBAY Profitability

Return on Equity

-36.05%

Return on Assets

-24.24%

Free Cashflow Yield

-1.96%

CBAY Fundamentals

CBAY Revenue

Revenue (TTM)

31.1M

Rev. Growth (Yr)

-99.79%

Rev. Growth (Qtr)

-100%

CBAY Earnings

Earnings (TTM)

-105.4M

Earnings Growth (Yr)

-57.33%

Earnings Growth (Qtr)

-23.67%

Breaking Down CBAY Revenue

Last 7 days

0.1%

Last 30 days

0.9%

Last 90 days

40.7%

Trailing 12 Months

255.0%

How does CBAY drawdown profile look like?

CBAY Financial Health

Current Ratio

10.96

CBAY Investor Care

Shares Dilution (1Y)

35.48%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	31.1M
2022	0	0	0	0
2021	0	0	0	0
2017	5.4M	7.7M	4.8M	10.0M
2012	12.1M	9.1M	6.1M	3.0M
2011	0	0	0	15.1M
2010	0	0	0	800.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cymabay Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2024	shantharam harish	back to issuer	-	-	-20,125	chief financial officer
Mar 22, 2024	wills robert james	back to issuer	-	-	-30,000	-
Mar 22, 2024	mcwherter charles	back to issuer	-	-	-46,938	president of r&d
Mar 22, 2024	quinlan paul t	back to issuer	-	-	-70,262	general counsel
Mar 22, 2024	emster kurt von	back to issuer	-	-	-90,000	-
Mar 22, 2024	shah sujal	back to issuer	-	-	-406,670	chief executive officer
Mar 22, 2024	dickinson klara	back to issuer	-	-	-21,000	chief regulatory officer
Mar 13, 2024	shah sujal	acquired	655,959	4.7151	139,119	chief executive officer
Mar 13, 2024	quinlan paul t	acquired	329,991	7.89	41,824	general counsel
Feb 12, 2024	dorling janet	acquired	27,780	4.63	6,000	-

Which funds bought or sold CBAY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Miracle Mile Advisors, LLC	sold off	-100	-590,500	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-1,890,280	-	-%
Apr 17, 2024	Clarius Group, LLC	sold off	-100	-211,116	-	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	sold off	-100	-1,849,710	-	-%
Apr 15, 2024	Legato Capital Management LLC	sold off	-100	-954,083	-	-%
Apr 11, 2024	Fortitude Family Office, LLC	sold off	-100	-1,134	-	-%
Apr 05, 2024	GAMMA Investing LLC	sold off	-100	-5,172	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	1,833	186,881	193,188	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	new	-	1,062,900	1,062,900	-%
Mar 11, 2024	VANGUARD GROUP INC	added	9.72	63,254,700	148,951,000	-%

Are Funds Buying or Selling CBAY?

Are funds buying CBAY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CBAY

No. of Funds

Unveiling Cymabay Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	janus henderson group plc	5.4%	6,103,797	SC 13G
Feb 14, 2024	commodore capital lp	0.0%	0	SC 13G/A
Feb 14, 2024	perceptive advisors llc	3.5%	4,024,400	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.99%	16,337,739	SC 13G/A
Feb 13, 2024	tcg crossover gp i, llc	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.56%	6,306,149	SC 13G
Jan 25, 2024	blackrock inc.	8.5%	9,610,239	SC 13G
Sep 22, 2023	ra capital management, l.p.	6.2%	6,940,000	SC 13G
Sep 11, 2023	adage capital partners gp, l.l.c.	3.76%	3,685,625	SC 13G
Mar 10, 2023	perceptive advisors llc	5.6%	5,278,962	SC 13G

Recent SEC filings of Cymabay Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	15-12G	15-12G
Mar 28, 2024	EFFECT	EFFECT
Mar 28, 2024	EFFECT	EFFECT
Mar 28, 2024	EFFECT	EFFECT
Mar 28, 2024	EFFECT	EFFECT
Mar 28, 2024	EFFECT	EFFECT
Mar 22, 2024	SC TO-T/A	SC TO-T/A
Mar 22, 2024	SC 14D9/A	SC 14D9/A
Mar 22, 2024	S-8 POS	Employee Benefits Plan
Mar 22, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to Cymabay Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Cymabay Therapeutics Inc News

Latest updates

Cymabay Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2017Q4	2017Q3	2017Q2	2017Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4	2010Q4
Revenue	-	57.00	-	31,016	27,329	23,642	19,955	16,268	12,581	8,894	5,207	-	-	4,793	13.00	2,913	-	-	-	-
Operating Expenses	32.1%	42,555	32,207	31,115	23,477	-	-	23,769	24,502	24,509	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	61.7%	19,806	12,245	11,578	7,247	-	-	5,878	6,087	6,104	-	-	-	-	-	-	-	-	-	-
R&D Expenses	14.0%	22,749	19,962	19,537	16,230	-	-	17,891	18,415	18,405	-	-	-	-	-	-	-	-	-	-
Interest Expenses	4.9%	5,081	4,843	4,618	4,075	-	-	3,648	3,365	2,061	234	258	283	305	-	-	-	-	-	-
Net Income	-23.7%	-41,902	-33,882	-808	-26,633	-	-	-27,094	-27,769	-26,543	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-Infinity%	-3.39*	-	-8.07*	-10.60*	-10.59*	-10.41*	-10.41*	-10.02*	-9.00*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-5.4%	-27,560	-26,151	-25,501	-18,769	-17,533	-22,564	-22,564	-25,362	-14,243	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.6%	435	451	227	245	142	159	178	201	202	123	117	137	154	168	177	189	206	232	253	274	187
Current Assets	-9.8%	404	448	224	243	138	155	167	192	191	120	114	133	152	166	174	186	203	228	250	270	182
Cash Equivalents	-24.5%	207	274	35.00	59.00	20.00	31.00	53.00	74.00	126	69.00	33.00	43.00	28.00	47.00	96.00	57.00	25.00	43.00	28.00	126	49.00
Net PPE	2.6%	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00
Liabilities	14.1%	142	125	118	141	106	99.00	95.00	93.00	69.00	36.00	10.00	9.00	11.00	12.00	11.00	14.00	19.00	19.00	17.00	17.00	16.00
Current Liabilities	87.3%	37.00	20.00	18.00	47.00	15.00	13.00	13.00	14.00	18.00	12.00	9.00	8.00	10.00	10.00	9.00	12.00	18.00	17.00	15.00	14.00	14.00
Shareholder's Equity	-10.4%	292	326	108	104	36.00	60.00	82.00	107	133	87.00	107	128	143	157	166	175	186	213	236	258	170
Retained Earnings	-4.5%	-978	-936	-902	-901	-872	-846	-821	-794	-766	-740	-717	-694	-676	-661	-649	-638	-625	-596	-570	-546	-523
Additional Paid-In Capital	0.6%	1,270	1,263	1,011	1,006	909	907	905	902	900	827	825	822	820	818	815	814	812	809	806	804	694
Shares Outstanding	0.5%	114	113	98.00	97.00	85.00	88.00	88.00	88.00	71.00	69.00	69.00	69.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	955	-	-	-	218	-	-	-	298	-	-	-	238	-	-	-	488	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-4.7%	-27,380	-26,151	-25,431	6,431	-18,756	-17,522	-22,440	-25,362	-14,243	-15,413	-19,214	-20,561	-14,816	-7,452	-7,749	-14,708	-28,136	-23,127	-24,254	-22,394	-19,595
Share Based Compensation	25.4%	4,669	3,724	3,350	3,487	2,361	2,350	2,392	2,414	2,385	2,549	2,557	2,505	1,811	2,552	963	1,998	2,075	2,865	2,276	2,342	1,738
Cashflow From Investing	-372.3%	-42,107	15,461	719	-60,642	8,356	-4,549	1,198	-50,990	-24,077	28,293	8,679	35,694	-4,349	-41,326	46,999	46,633	9,261	38,508	-73,072	-9,044	26,771
Cashflow From Financing	-98.9%	2,729	248,923	1,050	93,070	-	9.00	-	24,541	95,163	23,186	106	-	85.00	-	7.00	-	282	-	-167	108,017	24.00

CBAY Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 31,073	$ 0	$ 0
Operating expenses:
Research and development	80,799	67,995	64,542
General and administrative	51,953	25,116	23,040
Total operating expenses	132,752	93,111	87,582
Loss from operations	(101,679)	(93,111)	(87,582)
Other income (expense), net:
Interest income	13,490	2,017	167
Interest expense	(18,945)	(14,907)	(2,583)
Other income	1,764	0	0
Total other income (expense), net	(3,691)	(12,890)	(2,416)
Net loss	(105,370)	(106,001)	(89,998)
Other comprehensive (loss) income:
Unrealized gain (loss) on marketable securities, net of tax	470	(313)	(21)
Total other comprehensive income (loss)	470	(313)	(21)
Comprehensive loss	$ (104,900)	$ (106,314)	$ (90,019)
Basic net loss per common share	$ (0.99)	$ (1.21)	$ (1.27)
Diluted net loss per common share	$ (0.99)	$ (1.21)	$ (1.27)
Weighted average common shares outstanding used to calculate basic net loss per common share	106,204,273	87,804,063	71,055,331
Weighted average common shares outstanding used to calculate diluted net loss per common share	106,204,273	87,804,063	71,055,331

CBAY Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 206,535	$ 20,291
Marketable securities	187,720	115,194
Prepaid expenses and other current assets	9,547	2,588
Total current assets	403,802	138,073
Non-current marketable securities	21,932	0
Property and equipment, net	465	701
Right-of-use assets	5,260	169
Other assets	3,227	2,909
Total assets	434,686	141,852
Current liabilities:
Accounts payable	3,828	1,096
Accrued research and development expenses	5,633	6,530
Development financing liability - current portion	10,000	0
Deferred collaboration revenue - current portion	1,689	0
Other accrued liabilities	15,693	7,815
Total current liabilities	36,843	15,441
Development financing liability - non-current portion	99,172	90,227
Deferred collaboration revenue - non-current portion	1,100	0
Lease liabilities - non-current portion	5,315	30
Total liabilities	142,430	105,698
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 200,000,000 shares authorized; 113,864,976 and 84,681,063 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	11	8
Additional paid-in capital	1,270,328	909,329
Accumulated other comprehensive income (loss)	144	(326)
Accumulated deficit	(978,227)	(872,857)
Total stockholders' equity	292,256	36,154
Total liabilities and stockholders' equity	$ 434,686	$ 141,852

About Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CEO	Mr. Sujal A. Shah
WEBSITE	cymabay.com
INDUSTRY	Biotechnology
EMPLOYEES	60

Cymabay Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cymabay Therapeutics Inc? What does CBAY stand for in stocks?

CBAY is the stock ticker symbol of Cymabay Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cymabay Therapeutics Inc (CBAY)?

As of Mon Mar 25 2024, market cap of Cymabay Therapeutics Inc is 3.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CBAY stock?

You can check CBAY's fair value in chart for subscribers.

What is the fair value of CBAY stock?

You can check CBAY's fair value in chart for subscribers. The fair value of Cymabay Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cymabay Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CBAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cymabay Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CBAY is over valued or under valued. Whether Cymabay Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cymabay Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBAY.

What is Cymabay Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 25 2024, CBAY's PE ratio (Price to Earnings) is -35.36 and Price to Sales (PS) ratio is 119.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBAY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cymabay Therapeutics Inc's stock?

In the past 10 years, Cymabay Therapeutics Inc has provided 0.15 (multiply by 100 for percentage) rate of return.